- First subject dosed in Phase 1 clinical trial of EQ504 in Australia
- Triggers $20M milestone closing from August 2025 equity private placement (issuing ~15M shares)
- Extended cash runway expected to fund planned operations into 2029
?? Positive AI Sentiment (+3.5 / 10)